The investment will support Neobiomics’ continued commercial expansion, international growth, and further development of its portfolio within neonatal and pediatric health, it states.


Neobiomics is focused on developing and commercializing clinically documented nutritional products for vulnerable patient populations, with a particular focus on preterm infants.

“We are very pleased to welcome HealthCap as an investor and long-term partner,” said Emma Höglund, CEO of Neobiomics. “HealthCap brings deep life science expertise, a strong international network, and extensive experience in building global life science companies. This investment is an important milestone for Neobiomics and supports our ambition to bring evidence-based neonatal solutions to more infants worldwide.”


“Neobiomics is addressing this gap with a compelling and differentiated portfolio backed by strong clinical evidence and a proven commercial presence,” says Mårten Steen, Managing Partner at HealthCap.